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Abstract
Background: There is an ongoing discussion about age limits for deep brain stimulation (DBS).
Current indications for DBS are tremor-dominant disorders, Parkinson's disease, and dystonia.
Electrode implantation for DBS with analgesia and sedation makes surgery more comfortable,
especially for elderly patients. However, the value of DBS in terms of benefit-risk ratio in this
patient population is still uncertain.
Methods: Bilateral electrode implantation into the subthalamic nucleus (STN) was performed in
a total of 73 patients suffering from Parkinson's disease. Patients were analyzed retrospectively. For
this study they were divided into two age groups: group I (age <65 years, n = 37) and group II (age
≥ 65 years, n = 36). Examinations were performed preoperatively and at 6-month follow-up
intervals for 24 months postoperatively. Age, UPDRS motor score (part III) on/off, Hoehn & Yahr
score, Activity of Daily Living (ADL), L-dopa medication, and complications were determined.
Results: Significant differences were found in overall performance determined as ADL scores
(group I: 48/71 points, group II: 41/62 points [preoperatively/6-month postoperatively]) and in the
rate of complications (group I: 4 transient psychosis, 4 infections in a total of 8 patients, group II: 2
deaths [unrelated to surgery], 1 intracerebral hemorrhage, 7 transient psychosis, 3 infections, 2
pneumonia in a total of 13 patients), (p < 0.05). Interestingly, changes in UPDRS scores, Hoehn &
Yahr scores, and L-dopa medication were not statistically different between the two groups.
Conclusion: DBS of the STN is clinically as effective in elderly patients as it is in younger ones.
However, a more careful selection and follow-up of the elderly patients are required because
elderly patients have a higher risk of surgery-related complications and a higher morbidity rate.
Background
Chronic high-frequency deep brain stimulation (DBS) has
evolved into an established therapeutic approach for
treating patients with extrapyramidal movement disor-
ders, in particular patients with Parkinson's disease. DBS
effectively suppresses tremor and rigor as well as akinesia
and dyskinesia [1-14].
Numerous studies confirm the safety and efficacy of DBS.
Various targets have been used for suppressing specific
symptoms. The subthalamic nucleus (STN) is the pre-
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ferred surgical target for DBS in Parkinson's disease
[4,12,15-20].
Data on complications of the intervention are inconsist-
ent and cannot be compared. Adverse events associated
with STN stimulation are quite common with a high inci-
dence of mental changes though these are typically tran-
sient in nature [21-30].
Only limited data are available on the long-term clinical
course of patients after DBS surgery [31-34]. Because of
this lack of data, it has not been possible so far to defini-
tively answer questions regarding an age limit for DBS, a
possible loss of effectiveness over time, or potential neu-
roprotective effects of DBS [35-37]. The study presented
here aimed at determining whether STN DBS is as effective
in elderly patients as it is in younger ones and whether
there are any differences in the long-term outcome of
treatment between older and younger patients.
We therefore performed a retrospective analysis of all
patients who underwent electrode implantation for DBS
at two centers and were followed up for two years. Since
there were no significant differences in patient age and
performance, in the complication rate and in the results of
the DBS, we summarized the two centers. The patients
were divided into two age groups to compare results of
DBS in elderly individuals (> 65 years) with those in
younger patients (< 65 years). The clinical outcome and
complications of the operation and DBS were compared
between the two age groups.
Methods
A total of 73 patients were included in the statistical anal-
ysis, 51 patients operated on at center A and 22 patients
operated on at center B. The patients of both centers had
a mean history of Parkinson's disease at the time of sur-
gery of 14.6 years.
The patients were divided into two groups for analyzing
effects of age on outcome: Group I included 37 patients
aged up to 65 and group II included 36 patients aged 65
or above. The cut off was chosen because 65 year limit is
also known for therapy decisions e.g. in neurooncological
diseases, due to increased comorbidity in elderly patients
[38]. The age range of the total study population operated
on was 44 to 76 years (mean 64.1 ± 7.2 years). There was
no significant difference in the age distribution between
the two participating centers. For evaluation the patients
were summarized.
The patients were assessed using the Unified Parkinson's
Disease Rating Scale (UPDRS), the Activity of Daily Living
scale (ADL, Schwab and England), and the Hoehn & Yahr
scale. In addition, changes in medication as well as com-
plications and adverse events associated with surgery were
recorded. Complications were defined as all events that
considerably prolonged a patient's hospital stay or
required treatment because they impaired quality of life.
Adverse events were defined as stimulation-dependent
problems responding to changes in stimulation parame-
ters.
UPDRS data at 24-month follow-up were available from
42 of 51 patients in center A and from 16 of 22 patients in
center B. Stimulation parameters, Hoehn & Yahr scores,
ADL scores, and data on complications and adverse events
were available from all 73 patients.
Operative procedure
Electrodes were stereotactially implanted into the STN on
both sides in all patients. The intended target coordinates
relative to the mid-commissural point (MC) were as fol-
lows: x = ± 11 mm, y = -2 mm, and z = -2 mm. The target
coordinates were determined on the basis of ventriculog-
raphy, computerized tomography, and intraoperative
image fusion with a three-dimensional MRI dataset. Sur-
gery was initially performed under local anesthesia, later
with analgesia and sedation (propofol and alfentanil).
Since no revisions or removal of the electrodes under
external stimulation became necessary in any of the
patients, we dispensed with external stimulation in subse-
quent implantations since 1999. The pulse generator
(bilateral Itrel®  II until 1998; since 1999 Kinetra™,
Medtronic Inc., Minneapolis, MN, USA,) was implanted
under general anesthesia.
Statistical evaluation
Statistical testing of the results was done by multivariate
analysis using the Wilcoxon signed rank test and the one-
way ANOVA rank sum test (Sigmastat 1.0, Jandel Scien-
tific Inc, Chicago, IL, USA).
Results
Follow-up data after 24 months were available from 58
patients. UPDRS Part III scores showed a persistent
improvement of motor function (Fig. 1). No differences
between the two age groups and the two centers were seen
for the different conditions investigated (preoperatively
on medication/off medication and postoperatively on
stimulation/on medication, off stimulation/off medica-
tion, on stimulation/off medication, and off stimulation/
on medication) (Tab. 1). A lessening of the stimulation
effect or progression of the underlying disease was not
observed during the study period.
The Hoehn & Yahr scores showed a significant improve-
ment for the "medication off" and "stimulation on" state
(mean total score: 3.9 preoperatively versus 2.8* postop-
eratively, 2.6 at 6-month follow-up, and 2.7 at 24-monthBMC Neurology 2007, 7:7 http://www.biomedcentral.com/1471-2377/7/7
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follow-up, *p < 0.05, significant difference in scores
before and after stimulator implantation). The difference
was significant for the study population as a whole and for
the two age groups (p < 0.05). The differences between
two age groups were not significant (Fig. 2).
The patients' quality of life also improved significantly.
The ADL scores improved homogeneously in both groups
(Fig. 3). L-Dopa equivalent medication could be reduced
by a mean of 45% during the first 12 months after elec-
trode implantation (p < 0.01). The dose reduction was sig-
nificant for the total study population (n = 73) and for the
two age groups after 6 and 12 months (p < 0.01) (Fig. 4).
Stimulation parameters were constant during the first
twelve months after electrode implantation. For tremor-
Table 1: Mean values of UPDRS motor scores (part III) in all patients before surgery (with/without medication) and at postoperative 
follow-up after 6, 12, and 24 months: significant differences between preoperative med on vs. med off in all groups
Preoperative 12 months post 24 months post
med on med off stim on 
med on
stim on 
med off
stim off 
med on
stim off 
med off
stim on 
med on
stim on 
med off
stim off 
med on
stim off 
med off
total 30*,# 50**,# 2 0 * 2 8 * * 4 05 02 6 2 5 * * 4 45 4
<65 31*,# 51**,# 2 1 * 3 1 * * 3 85 02 7 2 1 * * 4 35 3
>65 30*,# 49**,# 1 8 * 2 5 * * 4 24 92 4 3 0 * * 4 85 6
(#p < 0.05, Dunn's method), med on vs. 12 m stim on/med on (*p < 0.05, Dunn's method), (24 m n.s.), preoperative med off vs. 12 m and 24 m stim 
on/med off (**p < 0.05, Dunn's method), no significant differences among the age group's and total of patient's
UPDRS motor scores (part III) in all patients before surgery (with/without medication) and at postoperative follow-up after 6,  12, and 24 months (preoperative medication on – preON, preoperative medication off: preOFF, postoperative stimulation on  and medication on) Figure 1
UPDRS motor scores (part III) in all patients before surgery (with/without medication) and at postoperative follow-up after 6, 
12, and 24 months (preoperative medication on – preON, preoperative medication off: preOFF, postoperative stimulation on 
and medication on).BMC Neurology 2007, 7:7 http://www.biomedcentral.com/1471-2377/7/7
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dominant Parkinson's disease higher frequencies were
used to suppress tremor symptoms. (Table 3)
Complications and side effects
A total of 27 complications, defined as unexpected events
prolonging a patient's hospital stay, occurred in 20
patients (Tab. 2). Severe complications were rare. One
patient suffered from symptomatic hemorrhage. The tran-
sient hemiparesis resulted in a complete recovery after 6
months. The two age groups differed with regard to the
death rate during the follow-up period and the incidence
of infections. One patient in group I committed suicide
after one year. Another 6 patients died from causes unre-
lated to the operation during the follow-up period. Infec-
tions were more common in group II (n = 1 vs. n = 4, p <
0.05). All but one infection occurred at the site of the
stimulator pouch. The remaining infection occurred at the
extension connector site. In all these cases the whole stim-
ulation system was explanted. Patient underwent systemic
specific antibiotic therapy for two weeks and oral therapy
for another 4 weeks. After 3 months reimplantation took
place. In all patients of this series the previous stimulation
effect could have been maintained.
Transient psychic deterioration frequently occurred in
both groups of patients. Although side effects of stimula-
tion were frequent, especially stimulation dependent dys-
arthria, there was no permanent neurological morbidity
in this study. By changing the stimulation parameters or
the active contacts, the effect of DBS was not diminished.
Discussion
Deep brain stimulation has evolved into an effective ther-
apeutic option for patients with advanced Parkinson's dis-
ease. The long-term benefit of this therapeutic approach
has been demonstrated in numerous studies. The cardinal
motor symptoms are suppressed most effectively when
the subthalamic nucleus is stimulated [4,39-53].
Hoehn and Yahr scores in all patients as well as in groups I and II preoperatively (with/without medication) and at follow-up  after 6, 12, and 24 months; significant differences between pre- and postoperative scores in all groups (**, #, § p < 0.05) Figure 2
Hoehn and Yahr scores in all patients as well as in groups I and II preoperatively (with/without medication) and at follow-up 
after 6, 12, and 24 months; significant differences between pre- and postoperative scores in all groups (**, #, § p < 0.05).BMC Neurology 2007, 7:7 http://www.biomedcentral.com/1471-2377/7/7
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While successful suppression of cardinal motor symptoms
is well established, only little data is available on the lim-
itations of DBS. Although DBS is supposed to be as effec-
tive in elderly patients as in younger ones, systematic
studies on the complication rate, the effectiveness and
therefore the risk-benefit ratio of DBS in elderly patients
are still lacking.
The two age groups investigated here were comparable
with regard to their baseline clinical status prior to DBS.
Both groups showed comparable improvement of the
motor subscale of the UPDRS (part III) and this improve-
ment was seen throughout the follow-up period of 24
months.
As DBS has become a routine therapeutic option, many
centers now strive to develop a quality standard by estab-
lishing uniform techniques of target localization and elec-
trode implantation. So far, no direct correlation has been
established between the generous use of imaging tech-
niques with microelectrode recording and a patient's out-
come. Nevertheless, state-of-the-art imaging techniques
for target definition (MRI, image fusion) are more and
more replacing the older methods such as ventriculogra-
phy [4,54-61]. The long-term results achieved by the two
participating centers did not differ although they used dif-
ferent techniques for defining and locating the targets of
electrode implantation (center A ventriculography and
stereotactic CT, center B stereotactic CT an image fusion
with contrast enhanced MPRAGE), suggesting that the
technique of target localization has no significant effect
on the results of DBS in our study population. Improve-
ment of motoric symptoms confirmed the efficacy of the
procedure in both groups. The rate of improvement corre-
Activity of Daily Living scores in all patients as well as in groups I and II preoperatively (with/without medication) and at the dif- ferent postoperative follow-up times; significant differences between pre- and postoperative scores in all groups (**, #, § p <  0.05) Figure 3
Activity of Daily Living scores in all patients as well as in groups I and II preoperatively (with/without medication) and at the dif-
ferent postoperative follow-up times; significant differences between pre- and postoperative scores in all groups (**, #, § p < 
0.05).BMC Neurology 2007, 7:7 http://www.biomedcentral.com/1471-2377/7/7
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sponds to the results of larger multicenter trials [62-64].
The medication doses could be reduced to the same extent
in both age groups. The dose reductions were in the range
reported in the literature [65-68].
A uniform definition of complications does not exist. This
is why complication rates reported in the literature vary
widely. Many studies did not report both mechanical
complications and psychic abnormalities associated with
STN stimulation. Those studies that report mechanical
complications provide only incomplete data on neuro-
logic and psychic changes. Even the multicenter studies
published so far present a very heterogeneous picture
[28,69-77]. Only the incidences of intracerebral bleeding
as the most severe complication and of infection as the
most common complication are reported by all investiga-
tors.
In the present study, we defined complications as all
events that prolonged a patient's hospital stay or/and
caused significant morbidity. The incidence of dementia
during the 2-year follow-up does not differ between the
Table 2: Complications in groups I and II
Total Group I <65 y (n = 37) Group II >65 y (n = 36)
Hemorrhage 0 1
Infections (generator) 1 4
Technique 1 2
Mental changes, transient 7 4
Mental changes, persistent 1 2
Death within 2 years 2 5
General (pneumonia) 2 2
total (patients) n = 12 (32%) n = 15 (42%)
only one death in group I was considered a complication (suicide 1 year after surgery)
L-dopa equivalents (mg) in all patients as well as in groups I and II preoperatively and at the different postoperative follow-up  times; significant differences between pre- and postoperative state in all groups (**, #, § p < 0.01), 24 m group I: ns Figure 4
L-dopa equivalents (mg) in all patients as well as in groups I and II preoperatively and at the different postoperative follow-up 
times; significant differences between pre- and postoperative state in all groups (**, #, § p < 0.01), 24 m group I: ns.BMC Neurology 2007, 7:7 http://www.biomedcentral.com/1471-2377/7/7
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two age groups and is the same as for the natural history
of Parkinson's disease. Mental alterations were frequent
after bilateral STN stimulation in both age groups (Tab.
2). These complaints were independent of stimulation.
There were retrospectively more related to withdrawal of
medication and operative stress. Further prospective eval-
uation was started to systematically analyze these symp-
toms. Reports in the literature again present a fairly
heterogeneous picture. Major differences existed between
both age groups with regard to the complications that
occurred: Infections were significantly more frequent in
the older age group than in the younger patients (p <
0.05). A total of 7 patients died during the 2-year follow-
up period. In 6 patients deaths were unrelated to surgery
(2 pneumonia, 1 suspected pulmonary embolism, 3
patients with cardiac failure, all deaths >6 months postop-
eratively). One suicide was determined to be related to
surgery. This particular patient suffered from a young
onset tremordominant Parkinson's disease and has had
no significant history of psychiatric disorders. After sur-
gery he developed transient manic-depressive state, which
were stimulation dependend, i.e. especially stimulation of
the lower two contacts led to a worsening of manic symp-
toms. Although motoric improvement was significant
under stimulation, psychic deteriorations limited the out-
come of the patient. With maximum stimulation of 1.5 V,
90 μs and 130 Hz, tremor was only partially influenced,
however without psychic symptoms. These symptoms led
also to a worsening of his however previously disturbed
social interactions of the patient. He got finally divorced
and he committed suicide 15 months after surgery. Not
counting the suicide, significantly more elderly patients
died (p < 0.05) compared with the younger age group.
This is not surprising if one takes into account natural life
expectancy. However, as shown by the results presented
here, the effectiveness of DBS is independent of patient
age. This is a supporting argument against an age limit for
DBS. Nevertheless, DBS should be contemplated as a ther-
apeutic option already in younger patients and in patients
with earlier stages of Parkinson's disease, for example, at
the time when complications of long-term levodopa ther-
apy first manifest themselves. With such an approach,
patients can benefit from STN stimulation for a much
longer period of time.
Prospective studies including a long-term follow-up of
STN DBS in young-onset Parkinson patients are being pre-
pared and will provide further evidence.
Conclusion
Bilateral DBS for Parkinson's disease is as effective in eld-
erly patients as it is younger individuals. Long-term obser-
vation identified no differences in the effect of DBS on
cardinal symptoms. Nevertheless, DBS should be consid-
ered in patients with early stages of disease as the inci-
dence of general complications increases with age while
natural life expectancy decreases. Most mechanical com-
plications can be avoided by using a standardized opera-
tive technique.
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